Abstract
Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Current Vascular Pharmacology
Title:Long-term Treatment of Venous Thromboembolism
Volume: 12 Issue: 3
Author(s): Cecilia Becattini and Giorgia Manina
Affiliation:
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Abstract: Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Export Options
About this article
Cite this article as:
Becattini Cecilia and Manina Giorgia, Long-term Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518154040
DOI https://dx.doi.org/10.2174/157016111203140518154040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-locoregional Therapy MRI Evaluation of Malignant Liver Lesions
Current Cancer Therapy Reviews To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Current Drug Targets Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Menstrual and Reproductive Outcomes Following Uterine Artery Fibroid Embolisation: A Literature Review
Current Women`s Health Reviews Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary Revascularisation
Current Cardiology Reviews Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Maternal Fibrinogen is Necessary for Embryonic Development
Current Drug Targets Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins
Current Drug Discovery Technologies Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Current Pharmaceutical Design Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Potential Pharmacological Applications of the Antithrombotic Molecule High Molecular Weight Kininogen
Current Vascular Pharmacology Future Prospects in Anti-Platelet Therapy: A Review of Potential P2Y12 and Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Current Vascular Pharmacology Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Metabolic Syndrome and Myocardial Infarction in Women
Current Pharmaceutical Design